Achim Rody
Experienced in Teratoma of the Mediastinum

Achim Rody

Ratzeburger Allee 160, 
Luebeck, SH, DE 
Experienced in Teratoma of the Mediastinum
Ratzeburger Allee 160, 
Luebeck, SH, DE 
OverviewLocationsClinical Research

Overview

Achim Rody practices in Luebeck, Germany. Mr. Rody is rated as an Experienced expert by MediFind in the treatment of Teratoma of the Mediastinum. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Endometrial Cancer, Hysterectomy, and Lymphadenectomy.

His clinical research consists of co-authoring 235 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Teratoma of the Mediastinum.

Gender
Male

Locations

Ratzeburger Allee 160, Luebeck, SH 23562, Germany
Other Locations
Ratzeburger Allee 160, Luebeck, SH 23538, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drug: Denosumab
Study Phase: Phase 3
View 1 Less Clinical Trial

235 Total Publications

Preferred working time models and equal opportunities in gynecology and obstetrics: a sub-analysis of the trinational FARBEN survey focusing on German participants from Western and Eastern federal states.
Preferred working time models and equal opportunities in gynecology and obstetrics: a sub-analysis of the trinational FARBEN survey focusing on German participants from Western and Eastern federal states.
Journal: Journal of the Turkish German Gynecological Association
Published: October 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Rody's expertise for a condition
ConditionClose
    View All 32 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile